Inventiva Aktie 35598121 / FR0013233012
5.79
EUR
0.04
EUR
0.70%
17:35:02
PAR
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 56.53 |
| BVF Partners LP | 19.93 |
| Frédéric Cren, MBA | 13.32 |
| NEA Management Co. LLC | 12.84 |
| Pierre Broqua, PhD | 9.21 |
| Sofinnova Partners SAS | 7.72 |
| Polar Capital Funds Plc - Biotechnology Fund | 2.37 |
| Candriam Equities L - Biotechnology | 1.55 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Personal am Ende des Jahres | 113 | 88 | 94 | 105 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.03 | 0.08 | 0.00 | 0.04 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Summe Umlaufvermögen | 72 | 49 | 132 | 115 |
| Summe Anlagevermögen | 62 | 42 | 120 | 98 |
| Summe Aktiva | 80 | 57 | 138 | 121 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 0 | 0 | 10 | 10 |
| Summe Fremdkapital | 18 | 16 | 28 | 33 |
| Summe Eigenkapital | 62 | 41 | 110 | 88 |
| Summe Passiva | 80 | 57 | 138 | 121 |
Adresse
| 50, rue de Dijon, 21121 Daix | |
| Telefon | +33 (3) 80-44-75-00 |
| URL | http://www.inventivapharma.com |
Management
|
Alice Roudot-Ketelers
Vice President-Clinical Operations |
|
Annick Schwebig
Independent Director |
|
Chris Buyse
Independent Director |
|
David Nikodem
Vice President-US Operations |
|
Eric Marie Albert Duranson
General Counsel |
|
Frédéric Cren
Chairman & Chief Executive Officer |
|
Heinz Christoph Mäusli
Independent Director |
|
Jean Volatier
Chief Financial & Administrative Officer |
|
Lucy Lu
Independent Director |
|
Martine Zimmermann
Independent Director |
|
Michael P. Cooreman
Chief Medical Officer |
|
Nathalie Harroy
Head-Human Resources |
|
Pierre Broqua
Director, Chief Scientific Officer & Deputy CEO |
